



LAW OFFICES OF
SYNNESTVEDT & LECHNER

2600 ARAMARK TOWER
1101 MARKET STREET
PHILADELPHIA, PA 19107-2950
TELEPHONE (215) 923-4466
FACSIMILE (215) 923-2189
E-MAIL synnleach@synnleach.com
www.synnleach.com

BT07 Rec'd PCT/PTO 28 JAN 2003
10/018030
CB

January 23, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re/ Application of G.H. Searfoss, III, M.F. Pagnoni,
Y.D. Ivashchenko, K. Guo and K.L. Clark
Application No. 10/018,030
Filed October 26, 2001


Examiner: Not Yet Assigned
Art Unit: Not Yet Assigned
Confirmation No.: Not Yet Assigned

Variants of TRAF2 Which Act as an
Inhibitor of TNF-Alpha (TNF α) Signaling Pathway

Attorney Docket No. P22,816-A USA

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope, postage prepaid, addressed to U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on January 23, 2003.


Nicole Lavery

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Reply to Notification of Defective Response of January 6, 2003
Regarding Compliance with Sequence Rules Under 37 C.F.R. §§1.821-1.825

Sir:

In response to the Notification of Defective Response, dated January 6, 2003,
enclosed herewith for filing are the following:

- (A) one diskette containing the Sequence Listing in computer-readable form;
- (B) the required statement concerning submissions of computer-readable copies of Sequence Listings subsequent to filing of the application, pursuant to 37

U.S. Application No. 10/018,030
S&L File No. P22,816-A USA


January 23, 2003
Page 2

C.F.R. §1.825(d); and

(C) a copy of the Notification of Defective Response.


Any Patent Office fee associated with this matter should be charged to Deposit
Account No. 19-5425. A duplicate of this transmittal letter is enclosed.

Respectfully submitted,


Jonathan M. Dermott, Ph.D.
Registration No. 48,608

SYNNESTVEDT & LECHNER LLP
Suite 2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
(215) 923-4466

M:\JDermott\Aventis Pharma\22.816-A USA\response to notification of defective reply of 2003-01-06.wpd



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box 901
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/018,030	FIRST NAMED APPLICANT George H. Searfos III	ATTY. DOCKET NO. P22,816A USA
INTERNATIONAL APPLICATION NO. PCT/US00/09178		
I.A. FILING DATE 04/06/2000		PRIORITY DATE 04/30/1999

Patrick J Kelly
Synnestvedt & Lechner
2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107-2950

ENHANCED CONFIDENTIAL

2-6-03

(no ext.)

CONFIRMATION NO. 3525
371 FORMALITIES LETTER

OC000000009325577

Date Mailed: 01/06/2003

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

FOR FILE	22816-A-USA
RECEIVED	
JAN 14 2003	
SYNNESTVEDT & LECHNER	
ATTN: PJB/RTL/MDS	

Applicant's response filed 09/23/2002 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 02/20/2002 have not been completed.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - Please review the CRF problem report attached to the notice.
 - APPLICANT MUST PROVIDE:
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an

amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

CHARITTA A BURT

Telephone: (703) 305-3734

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/018,030	PCT/US00/09178	P22,816A USA

FORM PCT/DO/EO/916 (371 Formalities Notice)